(EAY 131-X MATCH): Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
Description: 

The purpose of this study is to test any good and bad effects of Dasatinib in patients whose cancer has genetic changes called DDR2 mutations.

Study Number: 

NCG 275215 X

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02465060

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.